Proteome Sciences (PRM)

27.38p
   
  • Change Today:
      0.25p
  • 52 Week High: 41.00p
  • 52 Week Low: 17.25p
  • Currency: UK Pounds
  • Shares Issued: 192.50m
  • Volume: 19,836
  • Market Cap: £52.70m
  • RiskGrade: 292
  • Beta: 0.31

PRM Overview

Proteome Sciences is in the pharmaceuticals & biotechnology sector and is currently trading at 27.38p per share. In the last year Proteome Sciences's share price has ranged from 17.25p to 41.00p and brokers are currently rating this stock as 'neutral'.

1 Day Chart (25-05-2012)

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 49.4% -144.7%
ROCE 51.5%  
Latest F'cast
P/E 9.8 n/a
PEG n/a n/a
Pr/Revenue 5.3 22.4
Pr/Book 7.3  
Latest F'cast
Revenue 655.7% -76.2%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

PRM Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-06 0.07 (6.01) (3.51)p n/a n/a n/a n/a 0.0%
31-Dec-07 0.27 (5.46) (3.96)p n/a n/a n/a n/a 0.0%
31-Dec-08 0.85 (4.79) (3.46)p n/a n/a n/a n/a 0.0%
31-Dec-09 1.31 (4.20) (3.02)p n/a n/a n/a n/a 0.0%
31-Dec-10 9.87 4.59 2.79p 12.5 n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

PRM Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-11 2.35 (3.40) (1.65)p n/a n/a n/a n/a 0.0%
31-Dec-12 2.90 (3.20) (1.65)p n/a n/a n/a n/a 0.0%
31-Dec-13 12.25 5.70 1.60p 17.1 n/a n/a n/a 0.0%

Copyright © 2012 FactSet Research Systems Inc. All rights reserved.

PRM Company Announcements

Total Voting Rights 30-Apr-2012 07:00 RNS
Stroke biomarker license to Randox 05-Apr-2012 07:00 RNS
Block Admission Return 29-Mar-2012 17:11 RNS

Latest PRM Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

PRM Market Data

Currency UK Pounds
Share Price 27.38p
Change Today 0.25p
% Change 0.92 %
52 Week High 41.00p
52 Week Low 17.25p
Volume 19,836
Shares Issued 192.50m
Market Cap £52.70m
Beta 0.31
RiskGrade 292

PRM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.37% below the market average31.37% below the market average31.37% below the market average31.37% below the market average31.37% below the market average
2.13% above the sector average2.13% above the sector average2.13% above the sector average2.13% above the sector average2.13% above the sector average
Price Trend
38.16% above the market average38.16% above the market average38.16% above the market average38.16% above the market average38.16% above the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Income Not Available
Growth
69.44% above the market average69.44% above the market average69.44% above the market average69.44% above the market average69.44% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

PRM Dividends

No dividends found

Trades for 25-May-2012

Time Volume / Share Price
10:42 3,724 @ 27.06p
09:36 11,112 @ 27.00p
09:15 5,000 @ 27.93p

PRM Key Personnel

CEO Christopher Pearce
Finance Director James L Malthouse
COO Ian Pike

Top of Page